Large holder notice
Open the filing on sec.gov
Outlook Therapeutics, Inc. (OTLK)
Nasdaq: OTLK · Biological Products, (No Diagnostic Substances) · Iselin, NJ · filing with the SEC since 2015
The companyfiscal 2025, as filed
Revenue$1.4M
Net income-$62.4M+17.2%
Earnings per share$-1.79+55.9%
Operating cash flow-$51.8M+24.7%
Cash$8.1M-45.9%
Debtn/a
Shareholders’ equity-$32.2M+56.0%
Shares, diluted34.8M+87.6%
Return on equityn/a
The recordfrom its filings
Filings in 202672
Newest filingOct 13 · SCHEDULE 13G
Annual reportDec 19, 2025
Quarterly reportAug 18, 2026
Next report due10-K by Dec 29
Insider sales, 12 months$0.00
Insider buys, 12 months$7.9M
Patents granted3
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$61.1MCash from operations -$56.2Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Late quarterly report notice
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.